The global clinical chemistry analyzers market revenue was around US$ 13.6 billion in 2022 and is estimated to reach US$ 20.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2023 to 2031.
Clinical chemistry is a field of clinical pathology associated with the examination and analysis of body fluids that aid in illness diagnosis and treatment. They examine the metabolic functions to identify disorders like diabetes and screen for drug misuse. Clinical analyzers are automatic devices that use techniques like latex agglutination, ion-selective potentiometry, and photometric & colorimetric testing to analyze body fluids like plasma, blood serum, and urine.
Market Driving Factors
The prevalence of age-related disorders like diabetes, hypertension, liver, cardiovascular, and renal disease is anticipated to increase with the rapid growth of the senior population, which will further favorably influence the growth of the clinical chemistry analyzers market.
Increasing R&D activities surge the market growth. It is projected that continued R&D activities and the adoption of cutting-edge software technologies in clinical laboratories will define the future of clinical chemistry analyzers. Additionally, it's also feasible that players will develop new products in response to what laboratories demand. Participants in the clinical chemistry analyzers sector are creating customized analyzers for small-scale labs. Furthermore, manufacturers of clinical chemistry analyzers are rapidly developing smaller clinical chemistry analyzers, which creates the potential for enhanced testing capabilities.
The need for large capital investments and a lack of laboratory technicians with the necessary skills hamper the market growth.
Regional Analysis
North America dominated the market in terms of the highest shares during the projection period. This can be attributed to several factors, including an aging population, a rise in the prevalence of chronic diseases, supportive government policies, rising healthcare costs, a well-developed healthcare structure, and the accessibility of cutting-edge instruments.
Segmentation Insights
Test Insight
The basic metabolic panel (BMP) segment dominated the market in terms of shares. This can be attributed to the rising prevalence of lifestyle-induced disorders like obesity and other metabolic abnormalities. Furthermore, increasing importance and awareness of point-of-care testing is also one of the main factors toward segment share. This segment is a collection of tests that give medical examiners clinical details about issues brought on by chemical imbalances in the body.
End Use Insight
The hospital segment dominated the market. This can be attributed to the huge sample sizes, high readmission rates, and high patient volumes. Moreover, supportive infrastructure facilitates successful diagnostic procedures, resulting in a higher share in the segment. The rising number of government efforts targeted at encouraging effective diagnostic facilities to produce rapid outcomes and increase overall efficiency also serve as the key contributing elements in the market.
Prominent Companies
Segmentation Outline
The global clinical chemistry analyzers market segmentation focuses on Product, Test, End Use, and Region.
By Product
By Test
By End Use
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: CLINICAL CHEMISTRY ANALYZERS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 CLINICAL CHEMISTRY ANALYZERS
5.2.1 SMALL
5.2.2 MEDIUM
5.2.3 LARGE
5.2.4 VERY LARGE
5.3 CLINICAL CHEMISTRY REAGENTS
5.3.1 CALIBRATORS
5.3.2 CONTROLS
5.3.3 STANDARDS
5.4 OTHERS
6 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST
6.1 OVERVIEW
6.2 BASIC METABOLIC PANEL CLINICAL CHEMISTRY ANALYZERS
6.3 ELECTROLYTE PANEL CLINICAL CHEMISTRY ANALYZERS
6.4 LIVER PANEL CLINICAL CHEMISTRY ANALYZERS
6.5 LIPID PROFILE CLINICAL CHEMISTRY ANALYZERS
6.7 RENAL PROFILE CLINICAL CHEMISTRY ANALYZERS
6.8 THYROID FUNCTION PANEL CLINICAL CHEMISTRY ANALYZERS
6.9 SPECIALTY CHEMICAL TESTS CLINICAL CHEMISTRY ANALYZERS
7 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USE
7.1 OVERVIEW
7.2 CLINICAL CHEMISTRY ANALYZERS FOR HOSPITALS
7.3 CLINICAL CHEMISTRY ANALYZERS FOR ACADEMIC RESEARCH CENTERS
7.4 CLINICAL CHEMISTRY ANALYZERS FOR DIAGNOSTICS LABORATORIES
7.5 CLINICAL CHEMISTRY ANALYZERS FOR DIAGNOSTICS LABORATORIES
7.6 OTHERS
8 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 SIEMENS AG
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 JOHNSON & JOHNSON
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 HORIBA LTD
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 BECKMAN COULTER
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 MINDRAY MEDICAL INTERNATIONAL LTD
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 ORTHO-CLINICAL DIAGNOSTICS
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 ELITECH GROUP
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 ROCHE DIAGNOSTICS
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 ABBOTT DIAGNOSTICS
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 THERMO FISHER SCIENTIFIC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 RANDOX LABORATORIES LTD
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved